scispace - formally typeset
R

Ralf Wassmuth

Researcher at Dresden University of Technology

Publications -  13
Citations -  548

Ralf Wassmuth is an academic researcher from Dresden University of Technology. The author has contributed to research in topics: Transplantation & Mesenchymal stem cell. The author has an hindex of 7, co-authored 13 publications receiving 521 citations.

Papers
More filters
Journal ArticleDOI

Immunomodulatory properties of mesenchymal stromal cells and their therapeutic consequences for immune-mediated disorders

TL;DR: Bone marrow-derived mesenchymal stromal cells (MSCs) represent a population of nonhematopoietic cells, which play a crucial role in supporting hematopoiesis and can differentiate into various cell types such as osteocytes, chondrocytes, adipocytes, and myocytes.
Journal ArticleDOI

Estimation of high-resolution HLA-A, -B, -C, -DRB1 allele and haplotype frequencies based on 8862 German stem cell donors and implications for strategic donor registry planning

TL;DR: The results are highly relevant for strategic planning and resource allocation of donor centers and registries for outcomes of hematopoietic stem cell transplantation.
Journal ArticleDOI

Regional differences in HLA antigen and haplotype frequency distributions in Germany and their relevance to the optimization of hematopoietic stem cell donor recruitment.

TL;DR: Analysis of genetic distances suggests the existence of three regional clusters in South (regions 6-9), East (0-1), and Northwest (2-5) Germany, which shows most favorable characteristics with respect to haplotypic and phenotypic diversity and the occurrence of rare HLA antigens.
Journal ArticleDOI

Genetic Variations of Interleukin-23R (1143A>G) and BPI (A645G), but Not of NOD2, Are Associated with Acute Graft-versus-Host Disease after Allogeneic Transplantation

TL;DR: NOD2 SNPs did not predict aGVHD, but IL-23R(1142A>G) and BPI(A645G) SNPs appeared to be promising markers in this regard, and the importance of these markers in prediction models for GVHD and relapse remain to be defined in large prospective clinical trials.